Test Price
1,100 AED✅ Home Collection Available
H7N2 & Influenza A RNA Qualitative Detection Test in UAE | 1,100 AED | DNA Labs UAE
Executive Summary & Core Metrics
- Uncompromised Diagnostic Accuracy: 99.9% sensitivity and specificity via ISO 9001:2015 accredited Real-Time PCR and Whole Genome Sequencing.
- Premium Collection Logistics: Temperature-controlled cold-chain VIP home phlebotomy available daily from 8 AM to 11 PM across all Emirates.
- Integrated Clinical Support: Complimentary telephonic post-test consultation for comprehensive result interpretation and clinical guidance.
- Direct Insurance Billing: Hassle-free insurance verification and direct billing facilitated through our dedicated support line (WhatsApp +971 54 548 8731).
Test Overview & Methodology
The H7N2 & Influenza A RNA Qualitative Detection Test employs a dual-methodology approach combining quantitative Real-Time PCR (qPCR) with Whole Genome Sequencing (WGS). This advanced molecular strategy enables the definitive identification and subtyping of avian-origin influenza A (H7N2) directly from respiratory specimens. The qPCR component provides rapid, high-sensitivity initial screening, while WGS delivers comprehensive genomic characterization, which is critical for epidemiological surveillance, antiviral resistance profiling, and public health response coordination.
| Feature | DNA Labs UAE Assay (qPCR + WGS) | Rapid Antigen Test | Standard PCR (No WGS) |
|---|---|---|---|
| Methodology | qPCR + Whole Genome Sequencing | Immunochromatography | Real-Time PCR only |
| Sensitivity / Specificity | 99.9% / 99.9% | 50–70% / 90% | 95% / 99% |
| Subtyping (H7N2) | Confirmatory & Genomic | Not Available | Limited / Inconclusive |
| Turnaround Time | Phone Alert within 36h / Report 96h | 15 Minutes | 24–48 Hours |
| Clinical Actionability | High (Antiviral & IPC Guidance) | Low (Screening Only) | Moderate (Detection Only) |
Physician Insight & Safety Protocols
"From a primary care and infectious disease management perspective, this combined qPCR and Whole Genome Sequencing assay provides an indispensable layer of diagnostic precision for suspected cases of avian influenza. It facilitates early detection and accurate subtyping, which is vital for initiating appropriate infection control measures and targeted antiviral therapy. Clinical judgment, particularly regarding respiratory status and epidemiological risk factors, must always accompany the laboratory findings for optimal patient outcomes."
— Dr. Ajay Singh, General Practitioner, DHA Registration ID: 36234132
Clinical Safety Advisory for Respiratory RNA Assays
This qualitative detection assay demonstrates high analytic validity for H7N2 and Influenza A RNA. However, a negative result does not definitively exclude active infection if clinical exposure history is strongly suggestive. Optimal specimen collection (e.g., adequate cellular material, proper Viral Transport Medium handling) is critical for reliable RNA recovery and assay performance. Results should be interpreted in conjunction with complete blood counts, inflammatory markers, and chest imaging.
Patient Safety Exclusion Criteria & Emergency Red Flags
Exclusion Criteria: This test is designed for stable, ambulatory patients under clinical supervision. Patients with suspected co-infections requiring immediate hospitalization or those unable to provide informed consent should be referred directly to an emergency department.
Emergency Red Flags: Immediate medical attention is required if you experience severe respiratory distress, stridor, central cyanosis, SpO₂ below 92%, sudden confusion, hypotension, or hemoptysis. Do not wait for test results — proceed to the nearest Emergency Department without delay.
Patient FAQ & Clinical Guidance
1. What is the clinical accuracy of the H7N2 & Influenza A RNA test?
Our dual-methodology approach utilizing qPCR confirmed by Whole Genome Sequencing achieves over 99.9% sensitivity and specificity. This eliminates cross-reactivity with other respiratory viruses and provides definitive subtyping, which is essential for differentiating avian-origin influenza from seasonal influenza strains.
2. When can I expect my results after sample collection?
You will receive a preliminary telephonic notification within 36 hours of the laboratory receiving your sample. A comprehensive, certified digital report containing full genomic analysis data will be delivered securely via email within 96 hours (4 working days).
3. Are there specific sample collection requirements for RNA preservation?
Yes. Because RNA is inherently labile, specimen collection must be performed using a sterile flocked swab placed immediately into an approved Viral Transport Medium (VTM). Our DHA-licensed mobile phlebotomists are trained in strict cold-chain handling protocols to maintain specimen integrity from the point of collection to laboratory processing.
4. How does this test differ from standard rapid antigen tests available in pharmacies?
Standard rapid antigen tests detect viral proteins and have significantly lower sensitivity for influenza A subtypes (50-70%), particularly in asymptomatic or early-stage infections. Our qPCR and WGS approach detects the viral RNA genome itself, offering exponentially higher analytic sensitivity and the ability to track viral mutations and antiviral resistance markers.
UAE Regulatory & Data Privacy Adherence
Your Data. Protected. Compliant. Secure.
DNA Labs UAE operates under the strict regulatory framework of the Dubai Health Authority (DHA). We adhere rigorously to:
- Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) — ensuring your medical and genetic data is processed lawfully and transparently.
- Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields — guaranteeing the highest standards for digital health data storage and transmission.
- DHA Facility License No: 1143 — Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE.
- ISO 9001:2015 Certified (Certificate: INT/EGQ/2509DA/3139) — reflecting our commitment to quality management and continuous improvement.
Clinical & Logistical Metadata
| Test Name | H7N2 & Influenza A RNA Qualitative Detection (qPCR + WGS) |
| Price (AED) | 1,100 AED |
| Turnaround Time | Preliminary phone alert within 36 hours; certified digital report within 96 hours (4 working days) |
| Sample Type / Matrix | Nasopharyngeal or Oropharyngeal Swab in Viral Transport Medium (VTM) |
| Methodology Used | Real-Time PCR (qPCR) coupled with Whole Genome Sequencing (WGS) |
| ICD-10-CM Code | J09.X |
| LOINC Code | 60274-1 |
| DHA Facility License & Address | DHA License No: 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians